HKD 0.6
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 665.66 Million CNY | 0.76% |
2022 | 660.64 Million CNY | 14.03% |
2021 | 579.38 Million CNY | -80.07% |
2020 | 2.9 Billion CNY | 32.03% |
2019 | 2.2 Billion CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 571.24 Million CNY | -14.18% |
2024 Q2 | 571.24 Million CNY | 0.0% |
2023 Q4 | 665.66 Million CNY | 0.0% |
2023 Q1 | 692.56 Million CNY | 4.83% |
2023 Q3 | 665.66 Million CNY | -3.88% |
2023 Q2 | 692.56 Million CNY | 0.0% |
2023 FY | 665.66 Million CNY | 0.76% |
2022 FY | 660.64 Million CNY | 14.03% |
2022 Q4 | 660.64 Million CNY | 0.0% |
2022 Q3 | 660.64 Million CNY | -0.75% |
2022 Q2 | 665.66 Million CNY | 0.0% |
2022 Q1 | 665.66 Million CNY | 14.89% |
2021 FY | 579.38 Million CNY | -80.07% |
2021 Q4 | 579.38 Million CNY | 0.0% |
2021 Q3 | 579.38 Million CNY | -85.68% |
2021 Q2 | 4.04 Billion CNY | 25.33% |
2021 Q1 | 3.22 Billion CNY | 11.06% |
2020 Q1 | - CNY | 0.0% |
2020 FY | 2.9 Billion CNY | 32.03% |
2020 Q4 | 2.9 Billion CNY | 0.0% |
2020 Q3 | 2.9 Billion CNY | 0.0% |
2019 FY | 2.2 Billion CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -335.594% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 90.569% |